ClinicalTrials.gg
TerminatedNCT03444753Updated May 23, 2022

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

A Phase 1 interventional study of BMS-986299 and Nivolumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-23.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Why this study was terminated
business objectives have changed

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced/ solid tumor and to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
  • IO therapy resistant or insensitive tumors
  • Have at least 2 tumor lesions accessible for
  • Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Primary CNS
  • Participants with other active malignancy requiring concurrent intervention
  • Uncontrolled or significant cardiovascular disease

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Arm A

    BMS-986299

    Drug: BMS-986299

  • Experimental
    Arm B

    BMS-986299 in combination with nivolumab and ipilimumab

    Drug: BMS-986299 · Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • DrugBMS-986299

    Specified dose on specified day

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified dose on specified day

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs)

    Time frame: Up to 28 days

  2. Incidence of adverse events (AEs)

    Time frame: Approximately 2 years

  3. Incidence of clinical laboratory abnormalities

    Time frame: Approximately 2 years

  4. Incidence of serious adverse events (SAEs)

    Time frame: Approximately 2 years

  5. Incidence of AEs leading to discontinuation and deaths

    Time frame: Approximately 2 years

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 2 years

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Approximately 2 years

  3. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Approximately 2 years

  4. Area under the plasma concentration-time curve from time zero to 24 hours postdose [AUC(0-24)]

    Time frame: Approximately 2 years

07

Study locations

9 sites
  • Local Institution - 0003
    La Jolla, California 92093-0698, United States
  • Local Institution
    Orange, California 92868, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Local Institution
    New Haven, Connecticut 06520, United States
  • Local Institution
    Detroit, Michigan 48202, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Local Institution
    Portland, Oregon 97239, United States
  • Local Institution
    Pittsburgh, Pennsylvania 15232-1305, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Feb 2022, 46 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Feb 23, 2018
StartActual
Apr 5, 2018
Primary completionActual
Feb 14, 2022
CompletionActual
Feb 14, 2022
Last update
May 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444753
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Apr 5, 2018
Primary completion
Feb 14, 2022
Completion
Feb 14, 2022
Last update
May 23, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion